[go: up one dir, main page]

WO2014003232A1 - Composition comprenant un extrait de dendropanax morbifera léveille en tant que principe actif pour la favorisation de la pousse des cheveux - Google Patents

Composition comprenant un extrait de dendropanax morbifera léveille en tant que principe actif pour la favorisation de la pousse des cheveux Download PDF

Info

Publication number
WO2014003232A1
WO2014003232A1 PCT/KR2012/006104 KR2012006104W WO2014003232A1 WO 2014003232 A1 WO2014003232 A1 WO 2014003232A1 KR 2012006104 W KR2012006104 W KR 2012006104W WO 2014003232 A1 WO2014003232 A1 WO 2014003232A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
hwangchil
hair growth
present
hair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/006104
Other languages
English (en)
Korean (ko)
Inventor
최철희
조훈
문영숙
한지원
한주희
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chosun University Industry Academic Cooperation Foundation
Original Assignee
Chosun University Industry Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chosun University Industry Academic Cooperation Foundation filed Critical Chosun University Industry Academic Cooperation Foundation
Publication of WO2014003232A1 publication Critical patent/WO2014003232A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Definitions

  • the present invention relates to a composition for promoting hair growth comprising hwangchil wood extract as an active ingredient.
  • Hwangchil has been used as a rare paint that emits the golden color of emperor's armor, helmets, and other metal ornaments since the Three Kingdoms.It is a Korean envoy, written in the Goryeo Dynasty, China's Guilin History, Guilin, and Haedong History. It is written on the back, and it remains in the Tangbu History Book Book District, which is a special product of Baekje.
  • Hwangchil wood is effective in eliminating heat, detoxification, treating eye and jaundice, and leprosy and harmless to the human body (Lee Si-jin, Herbal Medicine, Chinese Moonlight Book, 1590).
  • Hwangchil wood extract having anticancer activity in Korean Patent Publication No. 2000-0004499, and Hwangchil extract, Hwangchil fraction and these having a hepatoprotective effect in Korea Patent Publication No. 2003-0079205
  • a pharmaceutical composition containing the same is described
  • Korean Patent Laid-Open Publication No. 2004-01077853 describes a hwangchil extract that inhibits ethanol-induced liver damage
  • Korean Patent Laid-Open Publication No. 2004-0107852 discloses a hwangchil extract and a hwangchil fraction having a skin whitening effect. It is described in the Korean Patent Laid-Open Publication No. 2005-0036093 discloses a sunscreen cosmetic composition containing the sap of sakchi wood as an active ingredient.
  • the present inventors completed the present invention by confirming that the hexane extract of the yellow lacquer tree leaf has an activity of promoting 15-PGDH enzymatic activity and promoting hair growth by increasing PGE2.
  • the present invention provides a cosmetic composition for promoting hair growth comprising hwangchil wood extract as an active ingredient.
  • the hwangchil wood extract may be a crude extract of the hwangchil wood, polar solvent soluble extract or non-polar solvent soluble extract.
  • the crude extract may be an extract available from a solvent selected from water, methanol, ethanol, butanol or a mixed solvent thereof, including purified water.
  • the non-polar solvent soluble extract may be an extract soluble in hexane, chloroform, dichloromethane or ethyl acetate.
  • the hwangchil wood extract (i) 15-PGDH enzyme activity inhibition; (ii) increased PGE 2 intracellularly and extracellularly; (iii) increased expression of cyclooxygenase-1 (COX-1) and multidrug resistance-associated protein4 (MRP4) genes; (iv) inhibition of prostaglandin transporter (PGT) expression; (v) Inhibition of 5 ⁇ reductase (5 ⁇ -R) expression; And (vi) androgen receptor (AR) expression inhibitory activity.
  • PTT prostaglandin transporter
  • RTT Inhibition of 5 ⁇ reductase
  • AR androgen receptor
  • the present invention provides a pharmaceutical composition for preventing hair loss, promoting hair growth, and improving the scalp, comprising the extract of Hilchi chinensis as an active ingredient.
  • the pharmaceutical composition may be selected from the group consisting of creams, gels, patches, sprays, ointments, warnings, lotions, linens, pasta and cataplasma as external skin preparations. have.
  • the present invention provides a health functional food for hair loss prevention, hair growth promotion and scalp improvement comprising an extract of Hwangchil as an active ingredient.
  • the food is selected from the group consisting of beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements Can be.
  • the present invention relates to a cosmetic composition for promoting hair growth comprising the extract of Hwangchil-tree as an active ingredient, a pharmaceutical composition for preventing hair loss, promoting hair growth and improving the scalp, and a functional food, and the extract of Hwangchil-tree according to the present invention has 15-PGDH activity.
  • the extract of Hwangchil-tree according to the present invention has 15-PGDH activity.
  • FIG. 1 is a schematic diagram showing the biosynthesis process of various PG (prostaglandins).
  • 3 is a picture of a hwangchil wood.
  • Figure 4 is a schematic diagram showing one process for producing a hwangchil wood extract of the present invention.
  • FIG. 5 is a schematic diagram of a PGEX-2T expression vector containing recombinant 15-PGDH.
  • FIG. 7 is a schematic of an experimental process for measuring PGE 2 using an ELISA kit.
  • Figure 9 is a graph of the cytotoxicity evaluation of Hwangchil-tree extract in HaCaT cells by MTT assay.
  • FIG. 10 is a graph showing the evaluation of cytotoxicity of Hilchi chinensis extract in LNCaP.FGC cells by MTT assay.
  • FIG. 11 is a graph showing the effect of increasing the concentration-dependent PGE 2 by the extract of Hilchi chinensis in A549 cells.
  • FIG. 12 is a graph showing the change of time-dependent extracellular PGE 2 concentration affected by Hwangchil extract DMHE in HaCaT cells.
  • FIG. 13 is a graph showing changes in intra-cellular and extra-cellular PGE 2 concentrations by H. chinensis extract DMHE in HaCaT cells.
  • Figure 14 is a graph showing the effect of DMHE on COX-1 / 2, MRP4, 15-PGDH and PGT mRNA expression in HaCaT cells.
  • 15 is a photograph confirming the hair growth promoting effect of DMHE using C57BL / 6 mice.
  • Figure 16 is a graph showing the effect on the expression of prostate specific antigen (PSA) mRNA of the Hwangchil-tree extract in LNCaP.FGC cells.
  • PSA prostate specific antigen
  • Figure 17 is a graph showing the effect on the expression of 5 ⁇ -R 1/2 mRNA of Hwangchil-tree extract in LNCaP.FGC cells.
  • FIG. 18 is a graph showing the effects on AR, 15-PGDH and PSA mRNA expression of DMHE and flutamide in LNCaP.FGC cells.
  • FIG. 18 is a graph showing the effects on AR, 15-PGDH and PSA mRNA expression of DMHE and flutamide in LNCaP.FGC cells.
  • FIG. 19 is a graph showing DMHE concentration-dependent effects on DHT-induced overexpression of AR and their target genes (15-PGDH and PSA) in LNCaP.FGC cells.
  • 20 is a graph showing the effect of PSA mRNA inhibition, which is a target gene of AR by DMHE, is restored by high concentration of DHT, and it is a graph showing the competitive inhibition with DHT for AR.
  • FIG. 21 is a graph showing that the DMHE of the present invention has an activity of inhibiting the concentration of 5 ⁇ R-1 gene in primary hair follicle dermal papilla cells (HFDPC).
  • HFDPC primary hair follicle dermal papilla cells
  • FIG. 22 is a graph showing that DMHE of the present invention has an activity of concentration-dependently inhibiting 5 ⁇ R-2 gene expression in primary hair follicle dermal papilla cells (HFDPC).
  • HFDPC primary hair follicle dermal papilla cells
  • FIG. 23 is a graph showing that DMHE of the present invention has activity of inhibiting expression of androgen receptor (AR) in HFDPC (primary hair follicle dermal papilla cells).
  • AR androgen receptor
  • DMHE of the present invention has an activity of inhibiting the expression of 15-PGDH, a target gene of androgen receptor (AR), in a concentration-dependent manner in primary hair follicle dermal papilla cells (HFDPC).
  • Extract is characterized in that crude extract, polar solvent soluble extract or non-polar solvent soluble extract of yellow lacquer tree.
  • “Crude extract” is a solvent selected from water containing purified water, lower alcohols having 1 to 4 carbon atoms such as methanol, ethanol, butanol, or a mixed solvent thereof, preferably a mixed solvent of water and methanol, more preferably 50 to 100% Extracts soluble in methanol.
  • Poly solvent soluble extract includes extracts soluble in water, methanol, butanol or a mixed solvent thereof, preferably water or methanol, more preferably methanol.
  • Non-polar solvent soluble extract includes extracts soluble in hexane, chloroform, dichloromethane, or ethyl acetate, preferably hexane, dichloromethane or ethyl acetate, more preferably in hexane or ethyl acetate solvent.
  • composition a mixture of the yellow lacquer extract of the present invention with other chemical components such as diluents or carriers.
  • a “carrier” is defined as a compound that facilitates the addition of a compound into a cell or tissue.
  • DMSO dimethyl sulfoxide
  • a “carrier” is defined as a compound that facilitates the addition of a compound into a cell or tissue.
  • DMSO dimethyl sulfoxide
  • a “carrier” is defined as a compound that facilitates the addition of a compound into a cell or tissue.
  • DMSO dimethyl sulfoxide
  • a "diluent” is defined as a compound that not only stabilizes the biologically active form of a compound of interest, but also is diluted in water to dissolve the compound. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline, because it mimics the salt state of human solutions. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely modify the biological activity of a compound.
  • an "effective amount” is an appropriate amount that affects a beneficial or desirable clinical or biochemical result.
  • An effective amount can be administered once or more.
  • an effective amount is an amount suitable to temporarily alleviate, ameliorate, stabilize, reverse, slow or slow the progression of a disease state. If the recipient animal can withstand the administration of the composition or if the administration of the composition to that animal is suitable,
  • the present invention relates to the use of the Hwangchil-tree extract, and relates to the exercise of the specific physiological activity and function contained in the Hwangchil-tree extract.
  • Hwangchil- tree ( Dendropanox morbifera LEV.) Is an evergreen broad-leaved arborescent tree belonging to the elm tree, and is a native species of Korea that grows on the south and west coasts such as Jeju Island, Wando, Bogildo, and Haenam (Fig. 3).
  • Cloves contained in Hwangchil Tree contain small amount of Terpene and Sesquiterpene, which are different depending on the time and place of collection, but germacrene-d, ⁇ -selinene, ⁇ -amorphene , ⁇ -selinene, ⁇ -cadinene, ⁇ -cadinene, T-muurolol, ⁇ -elemene, bicyclo [4,4,0] dec-1 -en-2 -isopropyl-5-methyl-9-methylene, ⁇ -cadinene , germacrene-B, ⁇ -copaene, ⁇ -humulene, ⁇ -cadinene and small amounts of linalool L, ⁇ -terpinene, ⁇ -cubebene, ⁇ -y GmbHe, (+)-calarene, 3,7-guaiadine, (-)- Contains isoledene, ⁇ -cubebene, limonene, aromadendrene
  • the part of the hwangchil wood that can be used in the present invention is not limited to leaves, stems, bark, etc., but preferably leaves can be used.
  • Hwangchil tree extract can be prepared and used by methods known in the art, modified methods thereof or the method according to the invention. As one embodiment, it can manufacture by the following method.
  • Hwangchil-tree extract or crude extract of the present invention is water, methanol, ethanol, butanol and the like containing about 1 to 30-fold volume, preferably 5 to 15-volume (w / v%) of purified water,
  • a solvent selected from a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, preferably a water and ethanol mixed solvent, more preferably 50 to 100% ethanol, is added at a temperature of about 0 to 100 ° C, preferably 10 to room temperature.
  • extraction method such as cold extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, or heat extraction method, preferably extracted by hot water extraction method, filtered and concentrated under reduced pressure to the yellow lacquer of the present invention Tree crude extract can be obtained.
  • the polar solvent or non-polar solvent soluble extract of the present invention is about 1 to 150 times the weight of the crude extract, preferably 50 to 100% ethanol crude extract, preferably 5 to 100 times the volume (w / v% ), Hexane, ethyl acetate and butanol are sequentially added to a volume of about 1 to 10 times, preferably 1 to 5 times, and fractionated 1 to 5 times, preferably 2 to 4 times.
  • the polar solvent and nonpolar solvent soluble extract of the invention can be obtained.
  • hexane extract can be obtained and used.
  • the concentrate of the extracts can be obtained in powder form through -80 °C freeze drying or 50 °C vacuum decompression.
  • the present invention includes a method for producing the hwangchil wood extract.
  • the preparation method is merely an exemplary method thereof, and may be suitably modified by various methods based on the art.
  • the non-exemplified extraction method according to the present invention may be used. Successful modifications can be made by those skilled in the art.
  • the present invention is based on the discovery of the molecular mechanisms of 15-PGDH activity and PGE 2 related mechanisms of the extract of Hilchi chinensis.
  • Hwangchil-tree extract of the present invention inhibits the activity of NAD + dependent 15-PGDH to increase the intracellular production of PGE 2 .
  • Prostaglandin is a mediator known as eicosanoid, produced from arachidonic acid liberated in cell membranes by physical, chemical, and specific cytokine growth factors and other stimuli. Biosynthetic processes of various PGs are shown in FIG. 1. In particular, PGE 2 is known as an important mediator of wound healing, peptic ulcer, eyebrow and hair formation, and bone formation. However, PGE 2 is rapidly metabolized by NAD + dependent 15-PGDH, so the half-life is very short in the body.
  • Hwangchil extract of the present invention has an excellent activity of increasing PGE 2 by inhibiting the 15-PGDH.
  • 15-PGDH enzyme activity inhibitory effect (ED 50 ) of the yellow leaves extract was 1.74 ⁇ g / mL to 661.8 ⁇ g / mL
  • n-hexane and ethyl acetate extracts showed ED 50 values of 1.74 ⁇ g / mL and 10.6 ⁇ g / mL, respectively.
  • hwangchil leaf hexane extract sikyeotgo the PGE 2 concentration-dependent increase in extracellular page A549 cancer cells, HaCaT cell line was increased in the cells and PGE 2 concentration outside the cell.
  • the hwangchil-tree extract of the present invention also affects the expression mechanism of other specific genes related to the mechanism.
  • the Hwangchil-tree extract of the present invention increased the expression of COX-1 and MRP4 mRNA, and decreased the mRNA expression of PGT and 15-PGDH.
  • the Hwangchil-tree extract has a hair growth promoting effect by inhibiting 15-PGDH activity.
  • Hair loss may be caused by disease, hair loss caused by hormonal causes, hair loss caused by nutritional imbalance, or hair loss caused by stress. Hair loss caused by the disease may be inherited, autoimmune diseases, burns, chemotherapy, psoriasis, Fungal infections, radiation exposure, or tumors may be the cause, and hair loss caused by the hormonal cause may be due to drugs, pre and postnatal pregnancy, menopause, diabetes, pituitary dysfunction, parathyroid or thyroid dysfunction.
  • PGE 2 promotes cell division and the head of the people in the body and to smooth the hair nutrition by expanding the blood in my veins accelerate the growth of hair.
  • Essential fatty acids are degraded to arachidonic acid by the PLA 2 enzyme and back to prostaglandins by the COX-2 enzyme, where 15-PGDH degrades prostaglandins in a NAD + dependent manner. Therefore, by inhibiting the action of 15-PGDH it is possible to inhibit the degradation of prostaglandins to promote hair growth or to prevent hair loss.
  • PGE 2 is also involved in the inflammatory response of the scalp to remove dandruff (Michelet JF et al., 2008, Exp. Dermatol, 17 (10), 821-8).
  • the hwangchil wood extract of the present invention has anti-androgen properties that inhibit the protein synthesis of AR.
  • the Hwangchil-tree extract of the present invention is involved in the suppression of AR signaling known as the main mechanism of androgenetic alopecia.
  • 5 ⁇ -reductase is an important enzyme that accelerates signaling to AR by converting testosterone to 5 ⁇ dihydroxytestosterone (DHT).
  • Finasteride a 5 ⁇ -reductase inhibitor, is used for the treatment of male hair loss (Propecia) and for the treatment of benign prostatic hyperplasia (BPH) (Proscar).
  • Hwangchil-tree extract of the present invention inhibits 5 ⁇ -reductase 1 and 2 and AR signaling by AR gene expression reduction and AR receptor blockade, resulting in a quantitative decrease of their target enzyme 15-PGDH.
  • DHT was shown to act as a competitive inhibition (AR) pattern for AR. That is, by interfering with the protein synthesis and activity of AR, the expression of 15-PGDH mRNA was reduced along with the target gene PSA. In the case of male hair loss, increased activity of AR and 5 ⁇ -reductase is reported as a major factor, and the hwangchil-tree extract of the present invention has a great effect on male hair loss.
  • this mechanism can have therapeutic and prophylactic effects even in diseases related to AR activity and 15-PGDH activity.
  • over-synthesized DHT binds to AR in prostate cells, leading to prostatic hypertrophy and even prostate cancer.
  • 5 ⁇ -R is also present in hair follicles of the scalp as well as converting testosterone to DHT for hair loss. Induced, it can be useful in the treatment of such diseases and hair-related cosmetic composition.
  • the hwangchil wood extract of the present invention inhibits 15-PGDH enzyme activity; Increasing intracellular and extracellular PGE 2 concentrations; Increased expression of cyclooxygenase-1 (COX-1) and multidrug resistance-associated protein4 (MRP4) genes; Inhibition of prostaglandin transporter (PGT) expression; And 15-PGDH activity based on this molecular mechanism because it inhibits 5 ⁇ -reductase gene expression, inhibits protein synthesis of androgen receptor (AR), also inhibits 15-PGDH expression, and is not toxic in laboratory animals. And the prevention and treatment of PGE 2 related diseases.
  • COX-1 cyclooxygenase-1
  • MRP4 multidrug resistance-associated protein4
  • the present invention provides a composition for hair growth, preferably a cosmetic composition for promoting hair growth, containing the extract of Hilchi chinensis as an active ingredient.
  • Alopecia is a disease associated with 15-PGDH activity, which refers to a symptom of hair loss, shortening the growth period in the hair cycle, and decreasing the proportion of growth hair in the total hair.
  • 15-PGDH activity refers to a symptom of hair loss, shortening the growth period in the hair cycle, and decreasing the proportion of growth hair in the total hair.
  • androgenetic alopecia the mechanism of its development is not known, but it depends on male hormones, and the proportion of resting hair follicles increases and the hair follicles become dwarfed.
  • the cosmetic composition according to the present invention may include components commonly used in cosmetic compositions, as well as extracts from the hwangchil wood, such as conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, And a carrier.
  • conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, And a carrier.
  • composition of the present invention can be used in addition to the above-mentioned Hwangchil-tree extract, a wool or hair-grown agent that has been conventionally used insofar as it does not impair the effect of hair loss (hair loss) and hair improvement by the Hwangchil-tree extract.
  • the cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair rinse, Hair Treatment, Hair Cream, Nutritional Cream, Hair Moisture Cream, Hair Massage Cream, Hair Wax, Hair Aerosol, Hair Pack, Hair Nutrition Pack, Hair Soap, Hair Cleansing Foam, Hair Oil, Hair Dryer, Hair Preservative, Hair Dye, Hair wave agent, hair bleach, hair gel, hair glaze, hair dresser, hair lacquer, hair moisturizer, hair mousse and hair spray can be prepared in various forms, but is not limited thereto.
  • the content of the hwangchil wood extract of the present invention is 0.00001-30% by weight, preferably 0.5-20%, more preferably 1.0-10% by weight based on the total weight of the composition.
  • the content of the Hwangchil-tree extract is less than 0.00001% by weight, the hair loss prevention and hair growth improvement effect by the Hwangchil-tree extract is greatly reduced, if it exceeds 30% by weight may cause skin irritation, and the problem of formulation have.
  • composition of the present invention may be a pharmaceutical composition comprising a hwangchil wood extract as an active ingredient.
  • the pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant may include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, Lubricants, flavors and the like can be used.
  • the pharmaceutical composition may be preferably formulated into a pharmaceutical composition including one or more pharmaceutically acceptable carriers in addition to the above-described active ingredient for administration.
  • Formulation forms of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops or injectable solutions.
  • the active ingredient may be combined with an oral, nontoxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture.
  • Suitable binders include but are not limited to natural and synthetic gums such as starch, gelatin, glucose or beta-lactose, corn sweeteners, acacia, trackercance or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
  • Acceptable pharmaceutical carriers in compositions formulated in liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA can be formulated according to each disease or component, as appropriate in the art.
  • the hwangchil wood extract of the present invention may be included in 0.00001 to 30% by weight relative to the total weight of the composition.
  • the external skin pharmaceutical composition of the present invention is a skin external preparation having the effect of preventing hair loss, promoting hair growth and improving the scalp, and includes cream, gel, patch, spray, ointment, warning, lotion, linen, pasta or cataplasma. It may be prepared and used as a pharmaceutical composition in the form of external preparations for skin, but is not limited thereto.
  • composition of the present invention may also be a food composition, which may contain various flavors or natural carbohydrates as additional ingredients, as well as ordinary food compositions, in addition to the extract of Hilchi chinensis as an active ingredient.
  • Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • the aforementioned flavoring agents can advantageously be used natural flavoring agents (tautin), stevia extracts (for example rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.).
  • the food composition of the present invention may be formulated in the same manner as the pharmaceutical composition, used as a functional food, or added to various foods.
  • Foods to which the composition of the present invention may be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice creams, alcoholic beverages, vitamin complexes, and health supplements. There is this.
  • the food composition is a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavoring agents, colorants and neutralizing agents (cheese, chocolate, etc.), pectic acid and its Salts, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like.
  • the food composition of the present invention may contain a fruit flesh for producing natural fruit juice and fruit juice beverage and vegetable beverage.
  • Hwangchil wood extract as an active ingredient of the present invention as a natural substance has little toxicity and side effects, so can be used with confidence even for long-term use for the purpose of preventing hair loss, promoting hair growth and improving the scalp.
  • the present invention also provides a health functional food for hair loss prevention, hair growth promotion and scalp improvement comprising the extract of Hilchi chinensis as an active ingredient.
  • the health functional food of the present invention can be produced and processed in the form of tablets, capsules, powders, granules, liquids, pills and the like for the purpose of preventing hair loss, promoting hair growth and improving the scalp.
  • health functional food refers to a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to the Health Functional Food Act No. 6767, and nutrients for the structure and function of the human body. It is meant to be consumed for the purpose of regulating or obtaining a useful effect for health use such as physiological action.
  • the health functional food of the present invention may include a conventional food additive, and the suitability as a food additive, unless otherwise specified, in accordance with the General Regulations of the Food Additives and General Test Methods approved by the Food and Drug Administration, etc. Judging by the standards and standards.
  • Food Additive Reduction examples include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as dark blue pigment, licorice extract, crystalline cellulose, high color pigment and guar gum; And mixed preparations such as sodium L-glutamate, algae additives, preservatives and tar dyes.
  • the health functional food in the form of a tablet is granulated in a conventional manner by mixing the mixture of excipients, hwangchil wood extract, an active ingredient of the present invention with excipients, binders, disintegrants and other additives, and then compressed with a lubricant and the like Or the mixture can be directly compression molded.
  • the health functional food in the form of tablets may contain a mating agent or the like as necessary.
  • Hard capsules among the health functional foods in the form of capsules may be prepared by filling a mixture of a mixture of additives such as excipients with the sulfur extract of the present invention in a conventional hard capsules, soft capsules are excipients, etc.
  • the mixture mixed with the additive of may be prepared by filling in a capsule base such as gelatin.
  • the soft capsule agent may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, as necessary.
  • the health functional food in the form of a cyclic form may be prepared by molding a mixture of Hwangchil-tree extract, an active ingredient of the present invention, an excipient, a binder, a disintegrant, and the like by a conventionally known method. It may be avoided, or the surface may be coated with materials such as starch, talc.
  • the health functional food in the form of granules can be prepared by granulating a mixture of Hwangchil-tree extract, an active ingredient of the present invention, an excipient, a binder, a disintegrant, and the like by a conventionally known method. And the like.
  • the health functional food may be beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements.
  • the present invention provides a use of the composition comprising a hwangchil wood extract for the production of cosmetics, medicine or food for preventing hair loss, promoting hair growth and scalp improvement.
  • the composition of the present invention containing the above-mentioned Hwangchil wood extract as an active ingredient can be used for the manufacture of cosmetics, medicine or food for preventing hair loss, promoting hair growth and improving the scalp.
  • the present invention provides a method for preventing or treating hair loss, comprising administering the extract of Hilchi chinensis to a mammal.
  • mammal refers to a mammal that is the subject of treatment, observation or experimentation, preferably human.
  • the term “therapeutically effective amount” means an amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, as thought by a researcher, veterinarian, doctor or other clinician, which Amounts that induce alleviation of the symptoms of the disease or disorder being treated. It will be apparent to those skilled in the art that the therapeutically effective dosages and frequency of administrations for the active ingredients of the present invention will vary depending on the desired effect. Therefore, the optimal dosage to be administered can be easily determined by one skilled in the art and includes the type of disease, the severity of the disease, the amount of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, general health of the patient.
  • Sex and diet Sex and diet, time of administration, route of administration and rate of composition, duration of treatment, and drugs used concurrently.
  • the hwangchil-tree extract of the present invention in the case of an adult, when the hwangchil-tree extract of the present invention is administered once to several times a day, it is preferable to administer at a dose of 1 mg / kg to 250 mg / kg.
  • the composition comprising the Hwangchil-tree extract of the present invention as an active ingredient may be administered through oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular or intradermal routes. It may be administered in a conventional manner.
  • the leaves of the Hwangchil tree (Dendropanax morbifera) were collected from a grain farm in Muan, Korea.
  • PGE 2 NAD +, NADH, glutathione-Sepharose 4B, dithiothreitol (DTT), sodium dodecylsulfate (EDS), EDTA, reduced glutathione, SC560 (COX-1 inhibitor), celecoxib (celecoxib, COX-2 inhibitor), naproxen (non-selective COX inhibitor), 5 ⁇ -dihydrotestosterone (DHT), mitomycin, sucralfate, carboxy methyl cellulose (CMC), and minoxidil to Sigma (St. Louis, MO, USA) and TGF- ⁇ 1 was obtained from Biovision Pharmacia Co. (New Jersey, USA).
  • the cDNA of human 15-PGDH was cloned from the human placental cDNA library (Cho and Tai, 2002). UV spectra were obtained using a Shimadzu RF-5301 IPC Fluorescence Spectrophotometer (Shimadzu, Japan).
  • PGE 2 enzyme immunoassay kit was purchased from Thermo Scientific (Rockford, IL, USA) and real-time PCR was performed with a Light Cycler 2.0 Instrument (Roche, Mannheim, Germany).
  • Analytical HPLC was performed using a Waters SunFire TM (4.6 ⁇ 150 mm, 5 ⁇ m) column on an Agilent HP1100 series consisting of a degasser, binary mixing pump, column oven and PDA detector.
  • Semi-preparative HPLC was performed using a Waters SunFire TM Prep C18 (10 ⁇ 250 mm and 19 ⁇ 150 mm, 5 ⁇ m) column with a Waters multisolvent delivary system combined with a DECASSIT TM 6342 degaser. All solvents used for plant extraction were HPLC grade
  • the dried leaves were extracted three times with methanol at room temperature.
  • the methanol extract was filtered using Whatman No. 1 filter paper and the combined methanol extract was concentrated in vacuo with a rotary evaporator.
  • the methanol extract was suspended in water and then fractionated respectively by polarity with hexane, diethyl ether, ethyl acetate, n-butanol and water. Each extract was concentrated with a rotary vacuum evaporator and this process is shown in FIG. 4.
  • Escherichia coli BL-21 DE3 cells were transformed with a vector as shown in FIG. 5, ie, a PGEX-2T expression vector containing recombinant 15-PGDH between the BamH I and EcoR I positions.
  • Cells were grown in 500 mL medium containing 50 ⁇ g / mL ampicillin under conditions of 37 ° C. and 220 rpm to incubate with an OD of 0.6 at 600 nm. Then IPTG (isoprophyl ⁇ -D-thiogalactoside, 1M stock solution) was added and the cells were incubated at 25 ° C. for 12 hours.
  • Cells are then obtained by centrifugation at 4000 xg at 4 ° C for 30 minutes and the cell pellets are resuspended in 20 mL of cold lysis buffer (1 x PBS buffer pH 7.4 containing 1 mM EDTA and 0.1 mM DTT) and sonicated. Decompose (4 x 10 s at 4 ° C). Crushed cells were centrifuged at 4000 xg for 20 minutes at 4 ° C.
  • the supernatant was then slowly applied to a Glutathione-Sepharose 4B column and equilibrated with lysis buffer at 4 ° C.
  • the column was washed with lysis buffer from O.D 280 up to 0.005 O.D.
  • 15-PGDH was eluted from the glutathione-Sepharose 4B column using an elution buffer (50 mM Tris-HCl pH 8.0 containing 10 mM reduced glutathione, 1 mM EDTA and 0.1 mM DTT) for 5 minutes at room temperature.
  • the concentration of 15-PGDH was measured by Bradford method (Schleicher and Wieland, 1978), and the purity of 15-PGDH (molecular weight 29KD) was confirmed by SDS-PAGE (sodium dodecyl sulfate polyacryl amide gel electrophoresis) and coomasine blue staining.
  • SDS-PAGE gels were stained with staining solution (0.1% Coomassie brilliant blue R 250, 50% methanol and 10% glacial acetic acid in water) for 20 minutes. The gel was washed several times with destaining solution (10% methanol, 7% glacial acetic acid in water) until the background of the gel was completely decolorized. Finally, the gel was stored in stock solution (5% glacial acetic acid in water) and scanned for detection.
  • staining solution 0.1% Coomassie brilliant blue R 250, 50% methanol and 10% glacial acetic acid in water
  • Activity analysis of 15-PGDH inhibitors was performed by measuring the formation of NADH at 468 nm and 340 nm using a fluorescence spectrophotometer.
  • Tris-HCl buffer 50 mM, pH 7.5
  • 0.1 mM DTT 0.25 mM NAD +
  • purified enzyme 10 ⁇ g
  • 21 ⁇ M PGE2 various concentrations of 15-PGDH inhibitor was added to each reaction mixture.
  • concentration was analyzed in triplicate.
  • the absorbance of the reaction mixture was corrected for 15-PGDH inhibitor activity from the standard curve of NADH in FIG. 6.
  • ED 50 values for 15-PGDH ranged from 1.7 ⁇ g / mL to 661.8 ⁇ g / mL depending on the extraction solvent.
  • HaCaT cells human keratinocyte cell lines, were incubated in Dulbecco's modified Eagle's media (DMEM) supplemented with 10% heat inactivated FBS, 100 ⁇ g / mL antibiotics, in a 5% CO 2 incubator at 37 ° C.
  • DMEM Dulbecco's modified Eagle's media
  • FBS heat inactivated FBS
  • 100 ⁇ g / mL antibiotics 100 ⁇ g / mL antibiotics
  • A549 cells derived from adecarcarnoma-like human alveolar type II were cultured in a 5% CO 2 incubator at 37 ° C. with RPMI medium.
  • LNCaP.FGC androgen-dependent prostate cancer cells were cultured in a 5% CO 2 incubator at 37 ° C. with RPMI medium. All cultured media were supplemented with 10% heat inactivated FBS and 100 ⁇ g / m L penicillin.
  • HaCaT cells (1 ⁇ 10 4 / mL), LNCaP.FGC cells (4 ⁇ 10 4 / mL) per 90 ⁇ L of DMEM medium were seeded in 96 well plates. After overnight incubation, the drugs were treated for 72 hours and incubated for 4 hours with 10 ⁇ L of MTT (5 mg / mL stock solution). Thereafter, the medium was removed and formazan was dissolved by adding 150 ⁇ L of DMSO. Absorbance was measured at 540 nm using an ELISA microplate reader (PerkinElmer, Calif ornia, USA).
  • IC 50 of hexane, ethyl acetate, methanol and water extracts of yellow lacquer tree ranged from 39.86 ⁇ g / mL to> 1000 ⁇ g / mL in HaCaT cells (FIG. 9), 88 ⁇ g / in LNCaP.FGC cells. It was found to be from mL to> 800 ⁇ g / mL ( Figure 10). In other words, the hydrophobic extract showed relatively high toxicity, but it was not fatal to cell viability.
  • COX and microsomal PGE synthase-1 (mPGES-1) -derived PGs-like PGE 2 are considered to be important regulators of pulmonary function.
  • PGE 2 production in infected sites modulates immune and inflammatory responses and is reported to be free by lung epithelial cells (N'Guessan et al., 2007).
  • Protein concentrations were determined by Bio-Rad protein assay based on Bradford (Schleicher and Wieland, 1978). Standard curves were prepared using serial dilution of bovine serum albumin (BSA), and Bio-Ra d protein assay staining reagents were diluted 1: 4 in water. 4 ⁇ L of standard and samples were added to 1 mL of diluted staining reagent and the absorbance was measured at 595 nm. Sample protein concentrations were determined from standard curves prepared with BSA.
  • BSA bovine serum albumin
  • HaCaT cells and A549 cells were seeded in 6-well culture plates in each medium of DMEM and RPMI containing FBS and antibiotics at 37 ° C. and in a wet 5% CO 2 incubator (5 x 10 5 cells / well), after treatment with different concentrations of 15-PGDH inhibitor, the supernatants were collected at specific times after media treatment. Intracellular and extracellular PGE 2 levels were measured using a PGE 2 enzyme immunoassay kit (Thermo Scientific, Rockford, IL, USA).
  • DMEA (1-, 2-, 3-fold ED 50 ), DMW (1-, 10-, 100-fold ED 50 ), DMHE (1-, 10-, 100-fold ED 50 ) and DMME (0.5-, 1- 2-fold ED 50 ) increased PGE 2 in a concentration dependent manner.
  • D. morbifera hexane extract (DMHE) inhibited 15-PGDH more efficiently.
  • Intra and extra PGE 2 levels are functionally related to gene expression levels of C OX-1 / 2, MRP4, 15-PGDH and PGT.
  • mRNA expression of COX-1 / 2, MRP4 and PGT was measured after DMHE (17.4 ⁇ g / mL) treatment in HaCaT cells.
  • the DMHE (17.4 ⁇ g / mL, 10 ⁇ ED50) concentration used in the assay used a concentration that showed sufficient 15-PGDH inhibitory activity without cytotoxicity from previous experiments.
  • total cell RNA was isolated from the cells using TRI reagents (RNAiso Plus, Takara).
  • RNA sample 20 ⁇ L was synthesized from each RNA sample (Invitrogen, USA).
  • PCR reactions included 4 ⁇ L of 1: 5 diluted cDNA, 4 mM MgCl 2 , 10 p mole of each primer and 4 ⁇ L of Fast Starter Mix buffer (dNTPs, SYBR Green dye and Tag polymerase).
  • dNTPs Fast Starter Mix buffer
  • Primers and conditions utilized for RT-PCR are as described in the table below. 5R 1 and 2 primers not listed in the table were purchased from Qiagen Korea Ltd. (Seoul, Korea) and used.
  • Each amplicon size was 185 bp, 119 bp and the annealing temperature was 5 seconds at 60 ° C., extension. Was carried out at 72 ° C. for 8 seconds.
  • PSA prostate s pecific antigen
  • the hwangchil extract of the present invention inhibited DHT-induced expression of PSA mRNA: n-Hex>EA>n-But> H 2 O extract in order.
  • non-flutamide DMHE also reduced the target genes, including PSA and 15-PDGH expression, by decreasing 5 ⁇ RI / 2 enzyme in DHT synthesis.
  • HFDPC Human Follicle Dermal Papilla Cells
  • the primary HFDPCs used in this experiment were all 3 4 passages, and the Follicle Dermal Papilla Cell growth medium (C-26501). , PromoCell) was cultured in a 37 ° C incubator with 5% CO 2, water. The jongbun to the culture HFDPC (5 x 10 5/6 well) DMHE then the cells are attached was administered 24 hours. Subsequently, the effects on the mRNA expression of 5 ⁇ R-1 and 5 ⁇ R-2 and AR involved in amplifying sensitivity to AR were examined by converting intracellular AR target genes, 15-PGDH and testosterone, into DHT.
  • C-26501 the Follicle Dermal Papilla Cell growth medium
  • the hwangchil extract of the present invention was shown to inhibit the expression of 5 ⁇ R-1 and 5 ⁇ -R2 concentration-dependently, in particular showed a stronger inhibitory effect on 5 ⁇ R-2.
  • minoxidil or bimatoprost used as a positive control also showed an inhibitory effect on 5 ⁇ R-1 or 5 ⁇ R-2, but did not show a concentration-dependent inhibitory effect like the hwangchil extract of the present invention (results not shown).
  • the present inventors have found that the hwangchil extract of the present invention has a sufficient role as an inhibitor of 15-PGDH activity and at the same time inhibits 15-PGDH expression by targeting AR signaling.
  • hair loss progression due to hyperactivation of AR signaling a major factor of male hair loss, simultaneously brings about 15-PGDH activity, a target gene, leading to a decrease in PGE2 around the scalp. Therefore, it can be seen that the hwangchil extract can be used to treat male hair loss as a substance having an excellent effect of blocking this mechanism and suppressing male hair loss mechanism.
  • Tablets containing Hwangchil-tree extract of the present invention obtained in the above Example as an active ingredient were prepared by the following method.
  • Lactose, starch and pregelatinized corn starch were mixed with the extract of Hilchi chile, and then a suitable volume of purified water was added and granulated into powder. The granules were dried and then mixed with magnesium stearate and compressed to obtain tablets.
  • the components of the tablet are as follows.
  • Capsules containing the hwangchil wood extract of the present invention as an active ingredient were prepared by the following method.
  • the hwangchil wood extract of the present invention was mixed with a certain amount of excipient and magnesium stearate. The resulting mixture was filled into gelatin capsules to obtain capsules.
  • the components of the capsule are as follows.
  • Injection solution containing the hwangchil wood extract of the present invention as an active ingredient was prepared by the following method.
  • the plant extract was dissolved in an appropriate volume of sodium chloride BP for injection, and the pH of the resulting solution was adjusted to pH 3.5 with dilute hydrochloric acid BP, then the volume was adjusted with sodium chloride BP for injection and thoroughly mixed.
  • the solution was filled into a 5 ml Type I ampoule made of transparent glass, and the glass was dissolved and enclosed under an upper grid of air, followed by autoclaving at 120 ° C. for at least 15 minutes to obtain an injection solution.
  • the components of the injection solution are as follows.
  • Methyl paraben 0.05 parts by weight
  • Moisturizer polyethylene glycol 200
  • the shampoo composition of the present invention was prepared using the following formulation.
  • the rinse composition of the present invention was prepared using the following formulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
PCT/KR2012/006104 2012-06-25 2012-07-31 Composition comprenant un extrait de dendropanax morbifera léveille en tant que principe actif pour la favorisation de la pousse des cheveux Ceased WO2014003232A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120068155A KR101487059B1 (ko) 2012-06-25 2012-06-25 황칠나무 추출물을 유효성분으로 포함하는 발모 촉진용 조성물
KR10-2012-0068155 2012-06-25

Publications (1)

Publication Number Publication Date
WO2014003232A1 true WO2014003232A1 (fr) 2014-01-03

Family

ID=49783352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/006104 Ceased WO2014003232A1 (fr) 2012-06-25 2012-07-31 Composition comprenant un extrait de dendropanax morbifera léveille en tant que principe actif pour la favorisation de la pousse des cheveux

Country Status (2)

Country Link
KR (1) KR101487059B1 (fr)
WO (1) WO2014003232A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230355544A1 (en) * 2019-12-03 2023-11-09 Sichuan Honghe Biotechnology Co., Ltd Pharmaceutical Composition Containing Elemene, Preparation Method Therefor, And Use Thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD789334S1 (en) 2015-12-01 2017-06-13 Samsung Electronics Co., Ltd. Stand for television receiver
WO2019107619A1 (fr) * 2017-11-30 2019-06-06 영어조합법인 제인 Procédé de fabrication d'une gelée comportant un extrait de dendropanax morbifera ajouté
KR102068523B1 (ko) * 2018-06-26 2020-01-21 곽민선 천일염을 이용한 탈모완화 및 발모촉진용 조성물
KR102171472B1 (ko) * 2018-10-23 2020-10-29 농업회사법인 휴림황칠(주) 황칠나무 잎 추출물 및 한라봉 껍질 추출물을 함유하는 발모개선조성물
KR102154058B1 (ko) 2019-06-20 2020-09-09 (주) 티나인 블루베리 및 마늘 껍질을 유효성분으로 함유하는 발모제의 제조방법
KR20250121165A (ko) 2024-02-01 2025-08-12 (주)바이오스트림 질경이 추출물을 포함하는 탈모 방지 및 발모 촉진용 조성물
KR102862715B1 (ko) * 2025-02-13 2025-09-23 (주)엘파운더 황칠나무 열매 추출물을 유효성분으로 함유하는 미세먼지에 의한 탈모를 완화 또는 개선하는 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000004499A (ko) * 1998-06-30 2000-01-25 박호군 항암 활성을 가지는 황칠나무 추출물
KR20110078527A (ko) * 2009-12-31 2011-07-07 주식회사 코리아나화장품 황칠나무 추출물을 유효성분으로 함유하는 화장료 조성물
KR101147984B1 (ko) * 2011-08-11 2012-05-24 허용기 황칠나무 추출물을 포함하는 모발용 조성물 첨가제 및 그 제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000004499A (ko) * 1998-06-30 2000-01-25 박호군 항암 활성을 가지는 황칠나무 추출물
KR20110078527A (ko) * 2009-12-31 2011-07-07 주식회사 코리아나화장품 황칠나무 추출물을 유효성분으로 함유하는 화장료 조성물
KR101147984B1 (ko) * 2011-08-11 2012-05-24 허용기 황칠나무 추출물을 포함하는 모발용 조성물 첨가제 및 그 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOON, YONG-SOOK: "The Biological Effects of Dendropanax morbifera Extracts: 15- Hydroxyprostaglandin Dehydrogenase Inhibition and Anti-androgenic Activities", GRADUATE SCHOOL, CHOSUN UNIVERSITY DOCTORATE THESIS, 24 February 2012 (2012-02-24), pages 42 - 53,61-86 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230355544A1 (en) * 2019-12-03 2023-11-09 Sichuan Honghe Biotechnology Co., Ltd Pharmaceutical Composition Containing Elemene, Preparation Method Therefor, And Use Thereof

Also Published As

Publication number Publication date
KR20140000813A (ko) 2014-01-06
KR101487059B1 (ko) 2015-01-27

Similar Documents

Publication Publication Date Title
WO2014003232A1 (fr) Composition comprenant un extrait de dendropanax morbifera léveille en tant que principe actif pour la favorisation de la pousse des cheveux
WO2021137677A1 (fr) Composition contenant un extrait de plante
WO2020122360A1 (fr) Procédé de préparation d'un extrait de zizania latifolia turcz. traité avec une enzyme présentant une teneur accrue en tricine, et composition de blanchissement, réduction des rides, anti-inflammatoire, antiallergique et d'hydratation, préparée avec ce dernier
WO2018124508A1 (fr) Composition pour la prévention et le traitement de maladies musculaires ou pour l'amélioration de la fonction musculaire, contenant de l'acide 3,5-dicaféoylquinique ou de l'extrait de chrysanthème
WO2013180336A1 (fr) Utilisation d'un extrait de dendropanax morbifera pour l'ajustement de l'activité de la 15-hydroxyprostaglandine déshydrogénase et de la pge2
WO2015111832A1 (fr) Composition de prévention ou de traitement de maladies liées à la prostate, contenant un extrait de poncirus trifoliata
WO2010123184A1 (fr) Composition pour prévenir et traiter l'alopécie, à base de composés de norgalanthamine
WO2015037778A1 (fr) Composition contenant un composé de lignane comme principe actif pour prévenir ou traiter un cancer
WO2020085826A1 (fr) Composition pour soulager une irritation de la peau induite par des facteurs de pollution environnementaux ou pour la protection de la peau, contenant comme principe actif un extrait de noix de muscade ou du macelignane
WO2018236186A1 (fr) Composition comprenant un dérivé de sesquiterpène en tant que principe actif pour la prévention ou le traitement de maladies musculaires
WO2010027221A9 (fr) Composition de blanchiment de la peau contenant un extrait, une fraction ou un compose issu de lindera erythrocarpa
WO2020218890A1 (fr) Composition consistant en un extrait d'actinidia polygama destiné à attenuer des lésions cutanées ou hydrater la peau
WO2020218720A1 (fr) Composition pour la prévention ou le traitement de troubles musculaires ou l'amélioration de la fonction musculaire, contenant un extrait de leonurus japonicus ou de la léonurine
WO2018062820A1 (fr) Composition visant à prévenir la chute des cheveux et à en favoriser la pousse, comprenant un phytoœstrogène en tant que principe actif
WO2015037855A1 (fr) Composition comprenant un extrait d'herbes combinées comprenant de l'acanthopanax koreanum naka et du crinum asiaticum var. japonicum présentant une activité de prévention de la calvitie et une activité de stimulation de la croissance capillaire
WO2010090498A2 (fr) Composition pharmaceutique et composition d'aliment naturel contenant un extrait de youngia denticulata, une fraction de celui-ci, ou un composé isolé à partir de celui-ci en tant que substance active pour améliorer la fonction hépatique
WO2018186641A1 (fr) Composition pour réduire les rides de la peau, hydrater la peau, améliorer son élasticité, l'exfolier, inhiber l'érythème ou réduire le photovieillissement de la peau, contenant du pipéronal ou l'un de ses sels à titre de principe actif
WO2020032435A1 (fr) Composition de prévention de la perte des cheveux ou de promotion de la restauration capillaire contenant du yarayara en tant qu'ingrédient actif
WO2019083286A2 (fr) Composition contenant de l'irone comme principe actif pour prévenir la chute des cheveux ou stimuler la repousse des cheveux
WO2011122805A2 (fr) Composition comprenant de l'ajoène destinée à prévenir ou à traiter une maladie due à la surexpression du lxr-alpha
WO2020040621A1 (fr) Composition visant à favoriser la différenciation ou la prolifération de cellules souches adipeuses humaines
WO2023113431A1 (fr) Nouvelle souche et son utilisation
WO2024080398A1 (fr) Peptide ayant des activités pour favoriser la croissance des cheveux et pour inhiber la chute des cheveux et son utilisation
WO2021187959A1 (fr) Composé à base de glucoside de glycérol et composition le comprenant pour protection contre la lumière ultraviolette ou anti-inflammation
WO2018186639A1 (fr) Composition pour réduire les rides cutanées, hydrater la peau, améliorer l'élasticité de la peau, exfolier la peau, inhiber les érythèmes ou réduire le photovieillissement de la peau, contenant de l'ionol ou un sel de celui-ci en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12880035

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12880035

Country of ref document: EP

Kind code of ref document: A1